Repligen supplies bioprocessing technologies used to manufacture biologic drugs such as monoclonal antibodies and gene therapies. Its portfolio includes filtration and chromatography systems, Protein A ligands, hollow-fiber filters and process analytics that help scale cell-culture and purification workflows. Customers are primarily biopharma companies and contract manufacturers seeking higher yield and efficiency in upstream and downstream production.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 182.4 | — | 14.9 | — |
| Q3 2025 | 188.8 | — | 14.9 | — |
| Q4 2025 | 197.9 | — | 13.3 | — |
| Q1 2026 | 194.3 | — | 8.3 | — |
| Q2 2026 | 204.1 | 11.9% | 5 | -66.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Li Auto Inc. (LI), Texas Roadhouse, Inc. (TXRH), The Cooper Companies, Inc. (COO), Skydance Corporation (PSKY), Jack Henry & Associates, Inc. (JKHY), SailPoint, Inc. (SAIL)